New China FDA Rules Allow Resumption Of Clinical Genome Sequencing
This article was originally published in PharmAsia News
Executive Summary
China's State FDA said it now has new rules in place covering the tools of the practice, allowing genome sequencing to resume in the country after a nearly five-month hiatus.